文库 R_医药、卫生 骨科

SupConFullGuideline.pdf

骨科指南与进展2011年-2013年 PDF   245页   下载0   2025-02-28   浏览5   收藏0   点赞0   评分-   429185字   10积分
温馨提示:当前文档最多只能预览 10 页,若文档总页数超出了 10 页,请下载原文档以浏览全部内容。
SupConFullGuideline.pdf 第1页
SupConFullGuideline.pdf 第2页
SupConFullGuideline.pdf 第3页
SupConFullGuideline.pdf 第4页
SupConFullGuideline.pdf 第5页
SupConFullGuideline.pdf 第6页
SupConFullGuideline.pdf 第7页
SupConFullGuideline.pdf 第8页
SupConFullGuideline.pdf 第9页
SupConFullGuideline.pdf 第10页
剩余235页未读, 下载浏览全部
THE TREATMENT OF PEDIATRIC SUPRACONDYLAR HUMERUS FRACTURES EVIDENCE-BASED GUIDELINE AND EVIDENCE REPORT AAOS Clinical Practice Guidelines Unit v1.0_092311 ii Disclaimer This Clinical Practice Guideline was developed by an AAOS physician volunteer Work Group based on a systematic review of the current scientific and clinical information and accepted approaches to treatment and/or diagnosis. This Clinical Practice Guideline is not intended to be a fixed protocol, as some patients may require more or less treatment or different means of diagnosis. Clinical patients may not necessarily be the same as those found in a clinical trial. Patient care and treatment should always be based on a clinician’s independent medical judgment, given the individual patient’s clinical circumstances. Disclosure Requirement In accordance with AAOS policy, all individuals whose names appear as authors or contributors to Clinical Practice Guideline filed a disclosure statement as part of the submission process. All panel members provided full disclosure of potential conflicts of interest prior to voting on the recommendations contained within this Clinical Practice Guidelines. Funding Source This Clinical Practice Guideline was funded exclusively by the American Academy of Orthopaedic Surgeons who received no funding from outside commercial sources to support the development of this document. FDA Clearance Some drugs or medical devices referenced or described in this Clinical Practice Guideline may not have been cleared by the Food and Drug Administration (FDA) or may have been cleared for a specific use only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. Copyright All rights reserved. No part of this Clinical Practice Guideline may be reproduced, stored in a retrieval system, or transmitted, in any form, or by any means, ele
SupConFullGuideline.pdf